MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Quanterix Corporation Cost of Revenue 2011-2026 | QTRX
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Quanterix Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 73.9 M | 54.3 M | 48.1 M | 58.7 M | 48.8 M | 38.2 M | 29.9 M | 19.7 M | 12.9 M | 9.84 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 73.9 M | 9.84 M | 39.4 M |
Quarterly Cost of Revenue Quanterix Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23 M | 13.2 M | 13.9 M | - | 15.7 M | 12.1 M | 13.5 M | - | 11.9 M | 11.5 M | - | 15.7 M | 14.8 M | 15 M | - | 12.4 M | 11.5 M | 10.9 M | 11.1 M | 10.3 M | 7.92 M | 8.91 M | 9.05 M | 7.91 M | 6.6 M | 6.33 M | 5.67 M | 5 M | 4.67 M | 4.35 M | - | 3.17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 23 M | 3.17 M | 10.6 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Viemed Healthcare
VMD
|
115 M | $ 9.21 | -0.11 % | $ 358 M |  USA |
 |
Varex Imaging Corporation
VREX
|
554 M | $ 10.82 | 0.37 % | $ 448 M | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Abbott Laboratories
ABT
|
19.3 B | $ 105.12 | 0.53 % | $ 183 B | USA |
 |
Vivos Therapeutics
VVOS
|
6.01 M | $ 1.12 | -5.88 % | $ 5.62 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Align Technology
ALGN
|
1.2 B | $ 165.94 | -6.42 % | $ 12.4 B | USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Beyond Air
XAIR
|
5.37 M | $ 0.68 | -1.74 % | $ 46 M | USA |
 |
Accuray Incorporated
ARAY
|
312 M | $ 0.39 | 4.43 % | $ 40.1 M | USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 11.05 | -4.12 % | $ 1.66 B | USA |
 |
Xtant Medical Holdings
XTNT
|
49.1 M | $ 0.57 | 0.5 % | $ 76.2 M | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
2.19 B | $ 88.45 | -0.79 % | $ 18 B | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Second Sight Medical Products
EYES
|
11.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 34.22 | -3.17 % | $ 5.1 K | USA |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 69.21 | -1.37 % | $ 102 B | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 35.63 | -2.76 % | $ 1.11 B | USA |
 |
NanoVibronix
NAOV
|
1.05 M | - | - | $ 1.08 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Cytosorbents Corporation
CTSO
|
10.5 M | $ 0.59 | -1.68 % | $ 32.1 M | USA |
 |
Aethlon Medical
AEMD
|
3.87 M | $ 2.22 | -2.2 % | $ 3.47 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.33 B | $ 79.12 | -3.63 % | $ 46.3 B | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 11.15 | -2.28 % | $ 1.51 B | USA |
 |
IRIDEX Corporation
IRIX
|
30.1 M | $ 0.97 | -28.14 % | $ 15.6 M | USA |
 |
Penumbra
PEN
|
461 M | $ 335.13 | -0.38 % | $ 13 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 15.76 | -3.64 % | $ 370 M | USA |
 |
LivaNova PLC
LIVN
|
448 M | $ 61.5 | -3.38 % | $ 3.35 B |  Britain |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
Ra Medical Systems
RMED
|
161 K | - | 10.0 % | $ 610 K | USA |
 |
Myomo
MYO
|
14 M | $ 0.68 | 0.43 % | $ 28.5 M | USA |
 |
Inspire Medical Systems
INSP
|
133 M | $ 49.39 | -2.1 % | $ 1.45 B | USA |
 |
Pulmonx Corporation
LUNG
|
23.4 M | $ 1.17 | -5.65 % | $ 47.6 M | USA |